Entero Healthcare Solutions Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Retailing | Market Cap: ₹6.2K Cr
Entero Healthcare Solutions targets consolidated revenue growth of approximately 23% year-on-year for FY27, excluding any major new acquisitions. Entero Healthcare projects a consolidated revenue growth of approximately 23% year-on-year for FY27, with a 5% EBITDA margin and 50% EBITDA to operating cash flow conversion.
From Entero Healthcare Solutions Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Price
₹1,648
Market Cap
₹6.2K Cr
P/E Ratio
48.0
Revenue Rank
Margin Rank
How does Entero Healthcare Solutions Ltd rank in Retailing?
Compare Entero Healthcare Solutions Ltd against every Retailing company this quarter on revenue, margins and earnings-call signals.
Entero Healthcare Solutions Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.9K Cr, net profit ₹45 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Entero Healthcare Solutions targets consolidated revenue growth of approximately 23% year-on-year for FY27, excluding any major new acquisitions.
- →The company aims to grow at an excess of 20% over the medium term (3 to 4 years), combining both organic and inorganic growth.
- →Focus for FY27 is primarily on organic growth by deepening existing relationships and expanding wallet share with current customers.
- →MedTech revenue is expected to cross INR 1,000 crores organically in FY27, contributing higher margins and growth.
- →Growth outperforming the industry (IPM) is driven by better service levels, wider product range, and stronger collaborations.
- →No major inorganic deals are planned in FY27, though small acquisitions may happen.
- →Long term vision targets sustained double-digit base growth and market share gains through industry consolidation.
📈 Profitability & Margins
Rank 2- →Entero Healthcare projects a consolidated revenue growth of approximately 23% year-on-year for FY27, with a 5% EBITDA margin and 50% EBITDA to operating cash flow conversion.
- →Over the medium term (3-4 years), the company targets growth exceeding 20% annually, driven primarily by organic growth.
- →EBITDA margins are expected to expand beyond 5%, with internal aspirations to exceed 6% due to operating leverage and procurement efficiencies.
- →Profit after tax (PAT) saw substantial growth in Q1, with a PAT margin of 2.7%; the company is focused on sustaining and building on this margin.
- →Return on capital employed (ROCE) and return on equity (ROE) are expected to improve, with ROCE projected in the 25-30% range over 3-4 years.
- →Incremental working capital needs are expected to be met internally, enabling potential debt reduction or further acquisitions to boost PAT.
- →MedTech segment growth, crossing INR 1,000 crores in FY27, is a major driver of margin expansion.
🏗️ Capital Expenditure Plans
Yes- →No explicit mention of major capex or strategic investments planned for FY27.
- →Management indicates there will not be any major acquisitions in FY27 but keeps options open for smaller deals.
- →Cash generated (50% of EBITDA converted to operating cash flow after working capital) will be deployed either for acquisitions, debt reduction, or buying out minority interests, whichever best enhances EPS.
- →Depreciation levels are expected to remain steady going forward, subject to no major capex.
- →Management emphasizes focusing on organic growth and improving existing business rather than large-scale inorganic expansion currently.
- →Opportunities for minor business exits or reducing low-margin businesses exist but will first be attempted to improve margins before letting go.
💰 Fundraising & Capital Structure
No information- →There is no explicit mention of new fundraising through debt or equity in the current quarter.
- →The company has INR200 crores of debt taken primarily for recent acquisitions, with full interest impact seen in Q1.
- →Future deployment of cash flow (after converting 50% of EBITDA to operating cash flow) may include acquisition funding, debt repayment, or minority buyouts based on what improves EPS the most.
- →No major acquisitions are planned in the near term, focusing on organic growth instead.
- →Acquisition funding and minority buyout funding can come from the parent or subsidiaries, with flexible options available.
- →Management remains open to compelling acquisition opportunities, especially towards the last quarter of the financial year.
- →Deferred decisions on interest costs and operational expenses over the year may influence future capital needs.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What Entero Healthcare Solutions Ltd's management said in earlier quarters
Others in Retailing this season
- Patel Retail (Q1 FY27)
INR 1 crore monthly revenue. Key concall takeaways from Patel Retail Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Credo Brands (Q1 FY27)
Profit after tax for Q1 FY27 was modest (INR 2.3 crores with 1.8% PAT margin), reflecting a phase of reinvestment. Key concall takeaways from Credo Brands…
- Aditya Birla Fashion & Retail Ltd (Q1 FY27)
10% space addition). Key concall takeaways from Aditya Birla Fashion & Retail Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- V2 Retail Ltd (Q1 FY27)
Volume growth of 56% was achieved in the latest quarter, aligned with store expansion. Key concall takeaways from V2 Retail Ltd's Q1 FY27 earnings call — and…
Frequently Asked Questions
What were Entero Healthcare Solutions Ltd Q1 FY27 results?
Entero Healthcare Solutions targets consolidated revenue growth of approximately 23% year-on-year for FY27, excluding any major new acquisitions. Entero Healthcare projects a consolidated revenue growth of approximately 23% year-on-year for FY27, with a 5% EBITDA margin and 50% EBITDA to operating cash flow conversion.
What is Entero Healthcare Solutions Ltd share price analysis?
Entero Healthcare Solutions Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 48.0 with a market cap of ₹6,196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Entero Healthcare Solutions Ltd planning capital expenditure?
No explicit mention of major capex or strategic investments planned for FY27.
Keep Entero Healthcare Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.